EANS-Adhoc: Oxygen Biotherapeutics to Voluntarily Withdraw Secondary Listing from SIX Swiss Stock Exchange

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

28.10.2011

MORRISVILLE, NC, October 27, 2011 - Oxygen Biotherapeutics, Inc.
(NASDAQ & SIX: OXBT) today announced that the SIX Swiss Stock
Exchange has approved the application filed by the company on
September 30, 2011, to remove the company's shares from trading on
the SIX exchange. This application was filed after the Company's
Board of Directors determined that the cost of maintaining the SIX
listing was not justified in light of the low trading volume of the
Company's shares over the past 12 months. The last day of trading
for the company's common stock on the SIX will be January 30, 2012.

Shares will continue to trade on the NASDAQ OMX under the symbol
OXBT.

end of ad-hoc-announcement ==========================================
====================================== About Oxygen Biotherapeutics,
Inc.

Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is
developing medical and cosmetic products that efficiently deliver
oxygen to tissues in the body. The company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product
called Oxycyte® that is being formulated for both intravenous and
topical delivery. The company has commercialized its DERMACYTE® line
of oxygen-rich skin care products. In addition, the company is
focused on PFC-based oxygen carriers for use in traumatic brain
injury, decompression sickness, and topical wound healing. See
www.oxybiomed.com for more information.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the
company that involve risks and uncertainties and reflect the
company’s judgment as of the date of this release. These statements
include the management transition, and expansion of research and
development of the Oxycyte product line, including the timing of the
introduction of these new products. The forward-looking statements
are subject to a number of risks and uncertainties including matters
beyond the company’s control that could lead to delays in new product
introductions and customer acceptance of these new products, and
other risks and uncertainties as described in our filings with the
Securities and Exchange Commission, including in the current annual
report on Form 10-K filed on July 15, 2011 and current quarterly
report on Form 10-Q filed on September 19, 2011. The company
disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.

Further inquiry note:
Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
One Copley Pkwy, Suite 490
Morrisville, NC 27560
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Oxygen Biotherapeutics Inc.
One Copley Parkway, Suite 490
US-27560 Morrisville, NC
phone: +1 (919) 855 21 12
FAX: +1 (919) 806 44 17
mail: e.corliss@oxybiomed.com
WWW: www.oxybiomed.com
sector: Biotechnology
ISIN: US69207P2092
indexes: SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange
language: English